Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: Case report I{cyrillic, ukrainian}lerlemiş hepatoselüler karsinomlu hastada muhtemelen Sorafenibe baǧ olan hiperkalemi

Üyetürk Ü., Budakoǧlu B., Helvaci K., Uysal Sönmez Ö., Türker I., Yalçintaş Arslan Ü., ...More

Turkiye Klinikleri Journal of Medical Sciences, vol.32, no.2, pp.585-587, 2012 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.5336/medsci.2010-21468
  • Journal Name: Turkiye Klinikleri Journal of Medical Sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.585-587
  • Keywords: Hepatocellular carcinoma, sorafenib, hyperkalemia, TUMOR LYSIS SYNDROME
  • Lokman Hekim University Affiliated: No


Sorafenib is an oral tyrosine kinase inhibitor used in the treatment of metastatic hepatocellular carcinoma (HCC). Its common adverse reactions include diarrhea, hand-foot syndrome, rash, cardiac ischemia or infarction, hypertension, elevated serum lipase and hypophosphatemia. A 35-year-old male patient with unresectable HCC was treated with sorafenib for progressive disease after locoregional chemoembolization. In the second month of the sorafenib treatment, he was admitted to the emergency department with weakness and drowsiness. His serum potassium level was 8.3 mmol/ L (3.5-5.5 mmol/L) which was accompanied with mild elevations in liver enzymes. Sorafenib treatment was stopped and emergency hemodialysis was applied. His potassium level reduced to normal levels and was stabilized. © 2012 by Türkiye Klinikleri.